Loading market data...
Thursday, July 2, 2026
Back to HomeKorea StockPremium

Isu Specialty Chemical Posts 9.8% Revenue Growth in Q1 2026, but Operating Profit Drops 42.9%

By MinJeKim0 views
Share
Isu Specialty Chemical Posts 9.8% Revenue Growth in Q1 2026, but Operating Profit Drops 42.9%
"

Isu Specialty Chemical (이수스페셜티케미컬, 457190.KS), a Korean fine chemicals producer spun off from Isu Chemical in May 2023, posted first-quarter 2026 revenue of KRW 108.6 billion (approximately USD 79 million), up 9.8% year-over-year, as brisk commercial goods sales offset a retreat in core product volumes. Yet operating profit tumbled 42.9% to KRW 3.5 billion and net income halved to KRW 1.9 billion, underscoring significant margin pressure from a shifting product mix and rising production costs.

Revenue Growth Driven by Commercial Goods

Consolidated net sales for the three months ended March 31, 2026 rose to KRW 108.6 billion from KRW 98.9 billion in the same period last year. The gain was concentrated in the commercial goods segment — which encompasses Base Oil, methyl ethyl ketone (MEK) and related intermediates — where revenue surged 44.7% year-over-year to KRW 42.0 billion, accounting for 38.7% of total revenue.

By contrast, the company's flagship fine chemical products division — producing mercaptan chain-transfer agents (TDM, NOM, NDM), isopropyl alcohol (IPA) and specialty solvents — posted a 4.9% year-over-year decline to KRW 63.8 billion, equivalent to 58.7% of the total mix. Average selling prices for the flagship Mercaptan product group edged down to KRW 4,784 thousand per tonne in Q1 2026 from KRW 4,921 thousand in FY2025, reflecting softer petrochemical feedstock markets.

Unlimited Korean-market analysis, $9.99/month

Isu Specialty Chemical Posts 9.8% Revenue Growth in Q1 2026, but Operating Profit Drops 42.9%

This article became available on July 1, 2026. Subscribe to read in full, or wait until September 29, 2026 when it becomes free.

Cancel anytime. Full refund within 7 days.

NewsFinanceMarkets

Go deeper than the headline

You just read what happened. Here's how to read what it means.

For news readers

Get news like this every morning

A short morning email summarizing the key KOSPI & KOSDAQ moves — earnings, disclosures, and foreign flows — in your inbox before the open.

$2.99 · monthly

Get the Morning Briefing
This filing

Full report on this filing

We read this company's latest DART filing in full — financials under K-IFRS, governance, and what it means for the stock. PDF in your inbox in 30–40 min.

$12 · one-time

Get the full report
Every name you watch

Follow the whole market

Reading several Korean stocks a week? Get on-demand analysis on any KOSPI or KOSDAQ company, whenever you need it.

$9.99 · monthly

Subscribe

Independent journalism based on primary DART filings — not investment advice. No brokerage affiliation.